To include your compound in the COVID-19 Resource Center, submit it here.

Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

By Brian Moy | Sep 7, 2018 | 4:45 PM GMT

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores

Read the full 161 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE